14 December 2018
EMA/PDCO/800778/2018
Inspections, Human Medicines Pharmacovigilance and Committees Division

Paediatric Committee (PDCO)

Minutes of the meeting on 13-16 November 2018

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

13 November 2018, 14:00- 19:00, room 3A

14 November 2018, 08:30- 19:00, room 3A

15 November 2018, 08:30- 19:00, room 3A

16 November 2018, 08:30- 13:00, room 3A

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO opinion is adopted), and on the opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Paediatric Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda was adopted and will be published on the EMA website.

1.3. Adoption of the minutes

The minutes of the October 2018 PDCO were adopted and will be published on the EMA website.

2. Opinions

Some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Evinacumab - EMEA-002298-PIP01-17

Regeneron Ireland U.C.; Treatment of elevated cholesterol / Treatment of homozygous familial hypercholesterolemia (HoFH)

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

An oral explanation took place with the PDCO, reflecting on the shortcomings identified by PDCO during the Day 90 discussion.
Following discussions with the Applicant, a positive opinion was adopted.

2.1.2. Semaglutide - EMEA-001441-PIP03-17

Novo Nordisk A/S; Treatment of obesity

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

The PDCO reviewed the applicant's response to the day 90 outstanding issues and the draft opinion for procedure EMEA-001441-PIP03-17 (semaglutide, treatment of obesity), during its plenary on 16 November 2018.
A positive opinion was adopted by the PDCO.

2.1.3. Ibrutinib - Orphan - EMEA-001397-PIP04-17

Janssen-Cilag International N.V.; Treatment of cGVHD / Treatment of cGVHD in children 1 year of age and older

Day 120 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO confirmed the views expressed at day 90 in relation to the condition, and accepted chronic graft versus host disease (cGvHD) as the condition of this PIP.
The PDCO issues a positive opinion for this PIP.

2.1.4. Rezafungin acetate - EMEA-002319-PIP01-17

Cidara Therapeutics, Inc.; Treatment of invasive candidiasis

Day 120 opinion

Infectious Diseases

Summary of committee discussion:

All issues raised at Day 60 are now resolved. The PDCO adopted a positive opinion, including a deferral.

2.1.5. Bilastine - EMEA-000347-PIP02-16

Faes Farma S.A.; Treatment of allergic conjunctivitis

Day 120 opinion

Ophthalmology

Summary of committee discussion:

All issued are considered resolved now. The PDCO adopted a positive opinion, including a deferral.

2.1.6. Bupivacaine - EMEA-000877-PIP03-17

Pacira Ltd; Postsurgical analgesia

Day 120 opinion

Pain

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the modified PIP proposal. As all outstanding issues have been resolved, the PDCO adopted a positive opinion.

2.1.7. Meloxicam / Bupivacaine - EMEA-002246-PIP01-17

Heron Therapeutics, B.V.; Acute Post Operative Pain

Day 120 opinion

Pain / Anaesthesiology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's modified PIP proposal. A positive opinion was adopted accordingly.

2.1.8. Synthetic double-stranded siRNA oligonucleotide targeted against transthyretin mRNA, with six phosphorothioate linkages in the backbone, and nine 2'-fluoro and thirty-five 2'-O-methyl nucleoside residues in the sequence, which is covalently linked via a phosphodiester group to a ligand containing three N-acetylgalactosamine residues - Orphan - EMEA-002425-PIP01-18

Alnylam Netherlands BV; Transthyretin-mediated amyloidosis

Day 60 opinion

Cardiovascular Diseases / Neurology

Summary of committee discussion:

Based on the assessment of this application the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Synthetic double-stranded siRNA oligonucleotide targeted against transthyretin mRNA, with six phosphorothioate linkages in the backbone, and nine 2'-fluoro and thirty-five 2'-O-methyl nucleoside residues in the sequence, which is covalently linked via a phosphodiester group to a ligand containing three N- acetylgalactosamine residues for all subsets of the paediatric population (0 to 18 years of age) in the condition treatment of Transthyretin-mediated amyloidosis.

2.1.9. Bruton's tyrosine kinase inhibitor - Orphan - EMEA-002438-PIP01-18

Principia Biopharma, Inc.; Treatment of Pemphigus

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO's view expressed at Day 30 was re-discussed and endorsed. A positive opinion was adopted at Day 60.

2.1.10. Anti-VEGF and anti-DLL4 dual variable domain immunoglobulin - EMEA-002420-PIP01-18

AbbVie Ltd.; Treatment of colorectal malignant neoplasms

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO noted that no additional information has been received in addition to what the Applicant outlined in the Summary Report.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Anti-VEGF and anti-DLL4 dual variable domain immunoglobulin for all subsets of the paediatric population (0 to 18 years of age) in the condition of Treatment of colorectal malignant neoplasms.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. The PDCO considered this product, based on its novel mechanism of action as promising for the paediatric population, potentially able to address an unmet need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.11. Palbociclib - EMEA-002146-PIP02-18

Pfizer Europe MA EEIG; Treatment of breast malignant neoplasms

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO's views expressed at Day 30 were endorsed, therefore based on the assessment of this application the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for palbociclib for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition 'treatment of breast malignant neoplasms'.
The members considered 'disease or condition for which the specific medicinal product is

intended occurs only in adult populations' as the most appropriate legal ground for the waiver since breast malignant neoplasms are extremely rare or almost not occurring in the paediatric population.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.
In principle, according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.12. Germanium (68Ge) chloride / Gallium (68Ga) chloride - EMEA-002436-PIP01-18

ITG Isotope Technologies Garching GmbH; Radiolabelling agent

Day 60 opinion

Other

Summary of committee discussion:

The PDCO re-discussed this procedure in light of the additional information received. The PDCO noted that indeed all relevant data concerning paediatric use are available. The PDCO concluded that the waiver ground of lack of significant therapeutic benefit is the most appropriate since no additional data are to be generated in order to reflect the needs of paediatric patients in the labelling.
Based on the assessment of this application the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Germanium (68Ge) chloride / Gallium (68Ga) chloride for all subsets of the paediatric population (0 to 18 years of age) in the condition of radiolabelling agent.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

2.2.1. Cobimetinib - EMEA-C2-001425-PIP01-13-M03

Roche Registration GmbH; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue) with Ras, Raf or MEK pathway activation

Day 30 letter

Oncology

Summary of committee discussion:

The PDCO discussed the completed study and considered that this is compliant with the

latest Agency's Decision (P/0216/2018) of 17 July 2018.
The PDCO finalised on 16 November 2018 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.

2.2.2. Dupilumab - EMEA-C2-001501-PIP01-13-M05

Regeneron Pharmaceuticals, Inc.,; Treatment of atopic dermatitis

Day 30 letter

Dermatology

Summary of committee discussion:

The PDCO discussed the completed study taking into account the applicant's additional clarifications and considered that it is compliant with the latest Agency's P/0158/2018 of 15 June 2018.
The PDCO finalised on 16 November 2018 this partially completed compliance procedure with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.

2.2.3. Belimumab - EMEA-C-000520-PIP01-08-M05

Glaxo Group Limited; Treatment of systemic lupus erythematosus

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The completed study was checked for compliance.
The PDCO considered that this study is compliant with the latest Agency's Decision (P/0183/2016) of 15/07/2016.
The PDCO finalised on 16 November 2018 this partially completed compliance procedure.

2.2.4. Ligelizumab - EMEA-C1-001811-PIP02-15-M02

Novartis Europharm Ltd.; Treatment of chronic spontaneous urticaria

Day 30 letter

Dermatology

Summary of committee discussion:

The partial compliance check has been finalised with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure. The PDCO was informed about the outcome of the procedure.

2.2.5. B/Brisbane/60/2008 (NYMC BX-35) as the B/Brisbane/60/2008-like virus / B/Phuket/3073/2013 as the B/Phuket/3073/2013-like virus / A/California/7/2009(NYMC X-179A) as the A/California/7/2009 (H1N1) pdm09-like

virus / A/Hong Kong/4801/2014 (NYMC X-263B) as the A/Hong Kong/4801/2014 (H3N2)-like virus - EMEA-C1-002027-PIP02-17

Adimmune Corporation; Prevention of influenza infection

Day 30 letter

Infectious Diseases

Summary of committee discussion:

The PDCO discussed the completed studies and considered that these are compliant with the latest Agency's Decision (P/0294/2017) of 04/10/2017. The PDCO finalised on 16 November 2018 this partially completed compliance procedure.

2.2.6. Perampanel - EMEA-C5-000467-PIP01-08-M10

Eisai Europe Ltd; Treatment of treatment-resistant epilepsies

Day 30 letter

Neurology

Summary of committee discussion:

The PDCO discussed the submitted additional information along with the assessors' comments and concluded that compliance cannot be confirmed now because the study has not been completed yet.

2.2.7. Atezolizumab - EMEA-C2-001638-PIP01-14-M01

Roche Registration GmbH; Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)

Day 30 letter

Oncology

Summary of committee discussion:

The partial compliance check has been finalised with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.

2.2.8. Entrectinib - EMEA-C1-002096-PIP01-16

Roche Registration GmbH; Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue neoplasms)

Day 30 letter

Oncology

Summary of committee discussion:

The partial compliance check has been finalised with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.

2.2.9. Mometasone (furoate) / Indacaterol (acetate) - EMEA-C1-001217-PIP01-11-M05

Novartis Europharm Limited; Treatment of asthma

Day 30 letter

Pneumology - Allergology

Summary of committee discussion:

The PDCO discussed the compliance check request and considered that all data have been generated as requested in the agreed PIP and that the deviations in wording of key elements and study report are minor and do not have an impact on the scientific conclusions. Therefore, the committee concluded that the completed studies are compliant with the latest Agency's Decision (P/0292/2018) of 12/09/2018.
The PDCO finalised this partially completed compliance procedure on 16 November 2018.

2.2.10. Fidaxomicin - EMEA-C-000636-PIP01-09-M07

Astellas Pharma Europe B.V.; Treatment of enterocolitis caused by clostridium difficile

Day 30 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO took note of preceding procedures and reports on partially completed compliance: EMEA-C1-000636-PIP01-09-M05.
The PDCO adopted on 16 November 2018 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0062/2018) of 16 March 2018.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Rabeprazole sodium - EMEA-000055-PIP01-07-M06

Eisai Limited; E16.4 Abnormal secretion of gastrin: Zollinger-Ellison Syndrome, K26 Duodenal Ulcer, K25 Gastric Ulcer, B96.8 Helicobacter pylori in patients with peptic ulcer disease, K21.0 Gastro-oesophageal reflux disease , treatment of symptomatic erosive or ulcerative gastro-oesophageal reflux disease (GORD); symptomatic treatment of moderate to very severe gastro-oesophageal reflux disease (symptomatic GORD), treatment in combination with appropriate antibacterial therapeutic regimens for the eradication of helicobacter pylori in patients with peptic ulcer disease

Day 60 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0055/2012 of 26 March 2012).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.2. Bedaquiline (fumarate) - Orphan - EMEA-000912-PIP01-10-M04

Janssen-Cilag International NV; Treatment of multi-drug resistant tuberculosis

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO discussed this modification at Day 60 during the November 2018 plenary.
In conclusion, the PDCO adopted a positive opinion during the November 2018 PDCO plenary.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0371/2016 of 4 January 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.3. Ceftobiprole medocaril sodium - EMEA-000205-PIP02-11-M03

Basilea Pharmaceutica International Ltd.; J15: Bacterial pneumoniae no elsewhere classified, J13: Pneumonia due to Streptococcus pneumoniae, J14: Pneumonia due to Hemophilus influenzae / Treatment of nosocomial pneumonia, Treatment of community acquired pneumonia

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO re-discussed the proposed changes taking into account the applicant additional clarifications.
Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that some but not all proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0317/2016 of 5 December 2016).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.4. Cobicistat / darunavir - EMEA-001280-PIP01-12-M02

Janssen-Cilag International NV; Treatment of HIV-1 infection / Treatment of HIV-1 infection in pediatric patients from 3 to less than 18 years

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO re-discussed the proposed modifications for darunavir / cobicistat taking into account the clarifications provided by the applicant.
In summary, based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0256/2017 of 4 September 2017).

2.3.5. Dolutegravir (DTG) - EMEA-000409-PIP01-08-M05

ViiV Healthcare UK Ltd.; B24 Unspecified Human Immunodeficiency Virus (HIV) disease / Treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

Upon request of the Coordinator the applicant provided further clarifications.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0061/2015 of 1/4/2015).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.6. Lamivudine (3TC) / Abacavir (ABC) / Dolutegravir (DTG) - EMEA-001219-PIP01-11-M04

ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus (HIV-1) infection / Treatment Human Immunodeficiency Virus (HIV-1) infection in paediatric population

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

Upon request of the Coordinator, the Applicant provided further clarifications
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0229/2017 of 9/8/2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.7. Pimodivir - EMEA-001975-PIP01-16-M02

Janssen-Cilag International NV; Treatment of influenza / to be used in combination with

oseltamivir for the treatment of acute influenza A in adults and children < 18 years of age with complicated influenza or at high risk for complications

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO re-discussed the proposed modification for pimodivir taking into account the clarifications provided by the applicant.
In summary, based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0135/2017 of 07 June 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.8. Fenfluramine hydrochloride - Orphan - EMEA-001990-PIP01-16-M02

Zogenix International Ltd; Dravet syndrome / the adjunctive treatment of seizures in paediatric patients at least 1 year of age with Dravet syndrome

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.9. Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - Orphan - EMEA-001862-PIP01-15-M01

Kite Pharma EU B.V.; Treatment of acute lymphoblastic leukaemia

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO assessed the answers provided by the applicant after Day 30 and found them acceptable.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0238/2017 of 9 August 2017).

The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.10. Tisagenlecleucel - Orphan - EMEA-001654-PIP01-14-M03

Novartis Europharm Limited; Treatment of B cell acute lymphoblastic leukaemia/lymphoblastic lymphoma / Treatment of CD19+ B cell acute lymphoblastic leukaemia (ALL) in paediatric patients whose disease is refractory to a standard chemotherapy regimen, relapsed after stem cell transplantation (SCT) or are ineligible for allogenic SCT.

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO confirmed all the conclusions reached at Day 30 and adopted a positive opinion at Day 60.
Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision P/0270/2017 of 22 September 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.11. Axicabtagene ciloleucel - Orphan - EMEA-002010-PIP01-16-M01

Kite Pharma EU B.V.; Treatment of mature B-cell neoplasms

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO assessed the answers provided by the applicant after Day 30 and found them acceptable.
Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0237/2017 of 9 August 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.12. Pazopanib - EMEA-000601-PIP01-09-M05

Novartis Europharm Limited; Ewing sarcoma family of tumours, rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma / Treatment of pediatric patients with rhabdomyosarcoma, treatment of pediatric patients with Ewing sarcoma family of tumours, Treatment of pediatric patients with non-rhabdomyosarcoma soft tissue sarcoma

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO assessed the answers provided by the Applicant after Day 30 and found them acceptable.
Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0163/2017 of 30 June 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.13. Ivacaftor / lumacaftor - EMEA-001582-PIP01-13-M08

Vertex Pharmaceuticals (Europe) Limited; Treatment of cystic fibrosis

Day 60 opinion

Other

Summary of committee discussion:

The PDCO re-discussed the proposed changes taking into account the additional clarifications by the applicant.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that many but not all of the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0005/2018 of 15 January 2018).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.14. Sildenafil - Orphan - EMEA-000671-PIP01-09-M10

Pfizer Limited; Treatment of Pulmonary Arterial Hypertension (PAH)

Day 60 opinion

Other

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0382/2017 of 19 December 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.4. Opinions on Re-examinations

2.4.1. Autologous CD34+ haematopoietic stem cells transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene - Orphan - EMEA-001974-PIP01-16-M02

Orchard Therapeutics Limited; Treatment of severe combined immunodeficiency due to

adenosine deaminase deficiency (ADA-SCID)

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO discussed this re-examination during the November 2018 plenary and noted the clarifications provided by the applicant. The Committee agreed with the arguments provided by the applicant.
Thus, the PDCO agreed to revise its opinion. The PDCO maintained this study as non-deferred.

2.5. Opinions on Review of Granted Waivers

No items

2.6. Finalisation and adoption of opinions

No items

2.7. Partial Compliance Checks completed by EMA

For the following partial compliance checks, no need to refer them to PDCO Committee for discussion, were identified by the PME coordinator and PDCO Rapporteur. The PDCO has been informed in writing.

2.7.1. Neisseria meningitidis serogroup B recombinant lipoprotein (subfamily A; Escherichia coli) / Neisseria meningitidis serogroup B recombinant lipoprotein (subfamily B; Escherichia coli) - EMEA-C2-001037-PIP02-11-M04

Pfizer Europe MA EEIG; Prevention of invasive meningococcal disease caused by N. meningitides serogroups B

Day 1 letter

Summary of committee discussion:

The partial compliance check has been finalised with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.

2.7.2. Dupilumab - EMEA-C3-001501-PIP01-13-M05

Regeneron Pharmaceuticals, Inc.; Treatment of atopic dermatitis

Day 1 letter

Dermatology

Summary of committee discussion:

The partial compliance check has been finalised with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.

2.7.3. Fenfluramine hydrochloride - EMEA-C4-001990-PIP01-16-M01

Zogenix International Ltd; Treatment of Dravet syndrome

Day 30 letter

Neurology

Summary of committee discussion:

The partial compliance check has been finalised with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.

3. Discussion of applications

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Etripamil - EMEA-002303-PIP01-17

Treatment of supraventricular tachycardia / Treatment of acute paroxysmal supraventricular tachycardia (PSVT)

Day 90 discussion

Cardiovascular Diseases

3.1.2. Givosiran sodium - Orphan - EMEA-002048-PIP02-18

Alnylam UK Limited; Acute Hepatic Porphyria (AHP) / Treatment of Acute Hepatic Porphyria (AHP)

Day 90 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.3. EMEA-001710-PIP04-17

Treatment of Crohn's disease

Day 90 discussion

Gastroenterology-Hepatology

3.1.4. Filgotinib - EMEA-001619-PIP03-16

Ulcerative colitis (UC), Crohn’s disease (CD) / Treatment of paediatric patients 2 years of age and older with moderately-to-severely active ulcerative colitis, treatment of paediatric patients 2 years of age and older with moderately-to-severely active Crohn’s disease

Day 90 discussion

Gastroenterology-Hepatology

3.1.5. Ianalumab - EMEA-002338-PIP01-18

Autoimmune hepatitis (AIH) / Treatment of autoimmune hepatitis in patients aged 8 years to <18 years in whom steroids and/or azathioprine are contraindicated, are not tolerated, or do not provide an adequate response

Day 90 discussion

Gastroenterology-Hepatology

3.1.6. Baricitinib - EMEA-001220-PIP04-17

Treatment of systemic lupus erythematosus

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.7. Iclaprim mesylate - EMEA-002391-PIP01-18

Infection with Gram-positive bacteria / Treatment of acute bacterial skin and skin structure infections

Day 90 discussion

Infectious Diseases

3.1.8. Rilpivirine (as free base) - EMEA-000317-PIP02-18

Treatment of human immunodeficiency virus (HIV-1) infection / In combination with cabotegravir long acting, treatment of HIV-1 infection in pediatric patients from 6 to less than 18 years of age who are virologically suppressed (HIV-1 RNA <50 copies/mL) and no known or suspected resistance to either rilpivirine or cabotegravir

Day 90 discussion

Infectious Diseases

3.1.9. Pexidartinib - Orphan - EMEA-001939-PIP03-16

Daiichi Sankyo Inc; Benign soft tissue neoplasms except tenosynovial giant cell tumour, Tenosynovial giant cell tumour / Treatment of debilitating tenosynovial giant cell tumour (TGCT), also known as pigmented villonodular synovitis (PVNS) and giant cell tumour of the tendon sheath (GCT-TS), in paediatric patients from 6 to 18 years where there is no other acceptable treatment

Day 90 discussion

Oncology

3.1.10. Split influenza virus, inactivated containing antigens equivalent to the B-like strain (Yamagata lineage) / Split influenza virus, inactivated containing antigens

equivalent to the B-like strain (Victoria lineage) / Split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain / Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain - EMEA-002359-PIP01-18

Prevention of influenza infection

Day 90 discussion

Vaccines

3.1.11. Budesonide - EMEA-002417-PIP01-18

Eosinophilic oesophagitis

Day 60 discussion

Gastroenterology-Hepatology

3.1.12. Bimekizumab - EMEA-002189-PIP02-18

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis) / Treatment of JIA (enthesitis-related arthritis [ERA] and juvenile psoriatic arthritis [JPsA]) in patients from ≥2 years to <18 years of age

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.13. Synthetic 47-amino-acid N-myristoylated lipopeptide - Orphan - EMEA-002399-PIP01-18

MYR GmbH; Chronic hepatitis D infection

Day 60 discussion

Infectious Diseases

3.1.14. Dexamethasone - EMEA-002423-PIP01-18

ICD10 H59.9 Postprocedural disorder of eye and adnexa

Day 60 discussion

Ophthalmology

3.1.15. (6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid. - Orphan - EMEA-002069-PIP03-17

Corbus Pharmaceuticals, Inc.; Treatment of Cystic Fibrosis

Day 60 discussion

Pneumology - Allergology

3.1.16. Amlodipine / Atorvastatin / Ramipril - EMEA-002416-PIP01-18

Treatment of essential hypertension (ICD9: 401, ICD10: I10), Treatment of Familial hypercholesterolemia (ICD9: 272.0, ICD10: E78.0) / For adults with hypertension and elevated cholesterol already controlled with ramipril, amlodipine and atorvastatin given concurrently at the same dose level as in the FDC (substitution indication).

Day 30 opinion

Cardiovascular Diseases

3.1.17. Indapamide / Telmisartan - EMEA-002462-PIP01-18

Treatment of hypertension

Day 30 discussion

Cardiovascular Diseases

3.1.18. Ralinepag - EMEA-002432-PIP01-18

Treatment of pulmonary arterial hypertension / Treatment of pulmonary arterial hypertension WHO Group I to improve exercise capacity and to delay clinical worsening

Day 30 discussion

Cardiovascular Diseases

3.1.19. Livoletide - Orphan - EMEA-002455-PIP01-18

Millendo Therapeutics SAS; Treatment of Prader-Willi syndrome

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.20. Emricasan - EMEA-002457-PIP01-18

Non-alcoholic steatohepatitis (NASH) / Treatment of NASH with moderate to severe liver fibrosis (F2-F4) in patients aged 8 to less than 18 years old

Day 30 discussion

Gastroenterology-Hepatology

3.1.21. Tropifexor - EMEA-002471-PIP01-18

Non-alcoholic steatohepatitis / Treatment of NASH with moderate to severe liver fibrosis (F2/F3) in paediatric patients from 8 to less than 18 years of age

Day 30 discussion

Gastroenterology-Hepatology

3.1.22. Turoctocog alfa pegol - Orphan - EMEA-001174-PIP03-18

Novo Nordisk A/S; Treatment of congenital haemophilia A

Day 30 discussion

Haematology-Hemostaseology

3.1.23. Humanized bispecific antibody against IL-4 and IL-13 - EMEA-001804-PIP03-18

Treatment of systemic sclerosis / Treatment of juvenile systemic sclerosis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.24. Humanized Anti-CD19, Fc Engineered, Monoclonal Antibody - Orphan - EMEA-002414-PIP01-18

Xencor, Inc.; Immunoglobulin G4-Related Disease / Treatment of adults, adolescents and children (> 23 months of age) with Immunoglobulin G4-Related Disease

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.25. Vedolizumab - EMEA-000645-PIP03-18

ICD-9-CM 279.51 / ICD-10-CM D89.810 - Other disorders involving the immune mechanism, not elsewhere classified: acute graft-versus-host disease

Day 30 discussion

Immunology-Rheumatology-Transplantation / Gastroenterology-Hepatology

3.1.26. Gepotidacin - EMEA-002443-PIP01-18

Treatment of Uncomplicated Urinary Tract Infections (uUTI) / Treatment of uncomplicated urinary tract infections (acute cystitis) in children aged >6 years to <18 years

Day 30 discussion

Infectious Diseases

3.1.27. Gepotidacin - EMEA-002443-PIP02-18

Treatment of uncomplicated Urogenital Gonorrhea (GC) / Treatment of uncomplicated urogenital gonorrhea in children aged ≥ 14 to <18 years

Day 30 discussion

Infectious Diseases

3.1.28. Rifamycin sodium - EMEA-002450-PIP01-18

Acute infections diarrhoea

Day 30 discussion

Infectious Diseases

3.1.29. Amantadine hydrochloride - EMEA-002460-PIP01-18

Treatment of Parkinson's disease and Parkinsonism

Day 30 discussion

Neurology

3.1.30. Recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein - Orphan - EMEA-002435-PIP01-18

PTC Therapeutic International Limited; Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency

Day 30 discussion

Neurology

3.1.31. Ronopterin dihydrochloride dihydrate - Orphan - EMEA-002473-PIP01-18

Vasopharm GmbH; Treatment of traumatic brain injury / Treatment of moderate and severe Traumatic Brain Injury (TBI) with Glasgow Coma Score (GCS) ≥ 3 and < 8 with presence of structural brain damage on CT (including contusion, mid-line shift) in children and adolescents aged 3-17 years.

Day 30 discussion

Neurology

3.1.32. Fibroblast activation protein alpha-targeted interleukin 2 variant immunocytokine - EMEA-002465-PIP01-18

Treatment of Non-small cell lung cancer

Day 30 discussion

Oncology

3.1.33. Niraparib (as tosylate monohydrate) - Orphan - EMEA-002268-PIP02-18

Tesaro UK Ltd; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid malignancies) / The combination therapy is for the treatment of patients ≥6 months to <18 years of age who have been diagnosed with recurrent solid tumours that exhibit a breast cancer susceptibility gene (BRCA)ness mutational signature (mutational signature 3)

Day 30 discussion

Oncology

3.1.34. anti PD-1 monoclonal antibody - EMEA-002463-PIP01-18

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid malignancies) / The combination therapy is for the treatment of patients ≥6 months to <18 years of age who have been diagnosed with recurrent solid tumours that exhibit a breast cancer susceptibility gene (BRCA)ness mutational signature (mutational signature 3)

Day 30 discussion

Oncology

3.1.35. Technetium (^{99}mTc) trofolastat chloride - EMEA-002441-PIP01-18

Treatment of prostate carcinoma

Day 30 discussion

Oncology / Uro-nephrology

3.1.36. Human ciliary neurotrophic factor - Orphan - EMEA-002477-PIP01-18

LE4D Ltd; Treatment of Macular Telangiectasia Type 2

Day 30 discussion

Ophthalmology

3.1.37. EMEA-002446-PIP01-18

Treatment of ichthyosis associated with Sjögren-Larsson Syndrome (SLS)

Day 30 discussion

Other / Endocrinology-Gynaecology-Fertility-Metabolism / Dermatology

3.1.38. EMEA-001976-PIP02-18

Asthma / Treatment to control persistent asthma

Day 30 discussion

Pneumology - Allergology

3.1.39. Roluperidone - EMEA-002222-PIP02-18

Treatment of Schizophrenia / Treatment of negative symptoms of schizophrenia

Day 30 discussion

Psychiatry

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Azilsartan medoxomil - EMEA-000237-PIP01-08-M08

Takeda Development Centre (Europe) Ltd.; Treatment of hypertension / Essential (primary) hypertension, Secondary hypertension

Day 30 discussion

Cardiovascular Diseases

3.3.2. Regadenoson - EMEA-000410-PIP01-08-M04

GE Healthcare AS; Myocardial perfusion disturbances

Day 30 discussion

Cardiovascular Diseases

3.3.3. Gadopiclenol - EMEA-001949-PIP01-16-M03

GUERBET; Detection and visualization of areas with disruption of the blood brain barrier and/or abnormal vascularity for the central nervous system (CNS) for diagnostic purposes

Day 30 discussion

Diagnostic

3.3.4. 2-hydroxypropyl-ß-cyclodextrin (HP-ß-CD) - Orphan - EMEA-001866-PIP01-15-M03

Mallinckrodt Pharmaceuticals Ireland Ltd; Treatment of Niemann-Pick disease, type C

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.5. Empagliflozin - EMEA-000828-PIP04-16-M02

Boehringer Ingelheim International GmbH; Treatment of type 1 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.6. Ethinyl estradiol / Dienogest - EMEA-002229-PIP01-17-M01

Exeltis France S.A.; Contraception / Oral contraception

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.7. Semaglutide - EMEA-001441-PIP01-13-M02

Novo Nordisk A/S; Diabetes Mellitus type 2 / Treatment of Diabetes Mellitus type 2

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.8. Naloxegol (as naloxegol oxalate) - EMEA-001146-PIP01-11-M04

Kyowa Kirin Pharmaceutical Development Limited; Treatment of opioid-induced constipation

Day 30 discussion

Gastroenterology-Hepatology

3.3.9. Potassium sulphate / magnesium sulphate heptahydrate / sodium sulphate anhydrous - EMEA-000816-PIP02-10-M02

IPSEN Pharma; Diagnostic of organic and/or functional bowel diseases / in adults and children from 6 months of age for bowel cleansing prior to any procedure requiring a clean bowel (e.g. bowel visualisation including endoscopy and radiology or surgical procedure) not a treatment for constipation

Day 30 discussion

Gastroenterology-Hepatology

3.3.10. Baricitinib - EMEA-001220-PIP01-11-M04

Eli Lilly and Company Limited; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis) / Treatment of juvenile idiopathic arthritis, Treatment of JIA-associated uveitis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.11. Fostemsavir (tromethamine) - EMEA-001687-PIP01-14-M03

ViiV Healthcare UK Ltd; Treatment of human immunodeficiency virus (HIV-1) infection / Treatment of HIV-1 infection as part of a combination therapy in paediatric patients who have no more than 2 remaining available fully active antiretroviral therapies

Day 30 discussion

Infectious Diseases

3.3.12. Rilpivirine (RPV) / Dolutegravir (DTG) - EMEA-001750-PIP01-15-M02

ViiV Healthcare UK Limited; B24 Unspecified Human Immunodeficiency Virus (HIV) disease / Treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection

Day 30 discussion

Infectious Diseases

3.3.13. Bivalent anti-human myostatin adnectin recombinant human IgG1-Fc fusion protein - EMEA-001793-PIP01-15-M03

Roche Registration GmbH; Treatment of Duchenne Muscular Dystrophy / Treatment of Duchenne Muscular Dystrophy in patients aged 2 years and older

Day 30 discussion

Neurology

3.3.14. Ocrelizumab - EMEA-000310-PIP03-10-M03

Roche Registration GmBH; Multiple Sclerosis / Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

Day 30 discussion

Neurology

3.3.15. Venetoclax - Orphan - EMEA-002018-PIP02-16-M01

AbbVie Ltd; Treatment of haematopoietic and lymphoid malignant neoplasms, Treatment of solid tumour malignant neoplasms / Treatment of a specific paediatric hematopoietic and lymphoid malignant neoplasm or of a solid malignant neoplasm as agreed by PDCO, in patients from 1 month to 18 years of age

Day 30 discussion

Oncology / Haematology-Hemostaseology

3.3.16. Birch Pollen Extract - EMEA-000809-PIP01-09-M01

Allergy Therapeutics (UK) Ltd; J.30.1 Allergic rhinitis due to pollen H10.1 Acute atopic conjunctivitis / allergic rhinitis/allergic conjunctivitis

Day 30 discussion

Pneumology - Allergology

3.3.17. Split influenza virus, inactivated containing antigen equivalent to A/ California/7/2009(H1N1)-like strain (A/California/7/2009 (NYMC X-179A)), adjuvanted - EMEA-000669-PIP01-09-M02

Sanofi Pasteur SA; Influenza / Prevention of infection by pandemic influenza virus (H1N1 strain) in the context of a pandemic

Day 30 discussion

Vaccines

4. Nominations

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 04 December 2018 for Nomination of Rapporteur and Peer reviewer

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

No items

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6. Discussion on the applicability of class waivers

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

No items

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

7.1.1. Ticagrelor - EMEA-000480-PIP01-08-M11

AstraZeneca AB; thromboembolic events (children), acute coronary syndrome, history of myocardial infarction / reduction in occurrence of vaso-occlusive crises in paediatric patients with sickle cell disease

Proposed indication: prevention of atherothrombotic events in adult patients with coronary artery disease and type 2 diabetes mellitus without a history of myocardial infarction or stroke

Cardiovascular Diseases / Haematology-Hemostaseology

Summary of committee discussion:

The PDCO confirmed that the proposed indication is included within the agreed PIP condition for this product.

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

No items

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

The PDCO members were informed about the final CHMP opinions on medicinal products with recommended paediatric indications adopted in October 2018. These included Dengvaxia, Flucelvax Tetra, Takhzyro and Kalydeco.

The list of procedures with paediatric indications to be evaluated by the CHMP, starting in October 2018, was presented to the PDCO members.

9.2.2. Committee for Medicinal Products for Human Use (CHMP)

CHMP/PDCO joint session

Summary of committee discussion:

The committees discussed medicines for severe asthma.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Karen van Malderen

Summary of committee discussion:

The Chair of the Non-clinical Working Group identified the products which will require Non-clinical Working Group evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

The Chair of the Formulation Working Group identified the products which will require Formulation Working Group evaluation and discussion.

9.4. Cooperation within the EU regulatory network

No items

9.5. Cooperation with International Regulators

No items

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No items

9.7. PDCO work plan

9.7.1. PDCO work plan 2019 proposal

PDCO member: Dirk Mentzer;

Summary of committee discussion:

The PDCO commented on the draft PDCO work plan 2019, to be adopted at the PDCO meeting December 2018.

9.8. Planning and reporting

No items

10. Any other business

10.1.1. Reflection paper on non-infectious liver diseases

PDCO Member: Johannes Taminiau

Summary of committee discussion:

The PDCO adopted the reflection paper on non-infectious liver diseases.

10.1.2. Art.57 database

Summary of committee discussion:

A general presentation on Art 57 was delivered, touching upon available content and how to access the database. The Committee noted that it would be useful to enhance the current export for the public with the addition of information on strength and pharmaceutical form of the medicinal product. Also, it was requested that further details on data available on 'paediatric indication' should be circulated, along with examples.

10.1.3. Report from the FDA cluster TC

Summary of committee discussion:

The committee was informed about the discussions at the paediatric cluster T-conference. The dates of next year cluster T-conferences will be included in the post-mail.

11. Breakout sessions

11.1.1. Paediatric oncology

Summary of committee discussion:

The group discussed topics related to currently ongoing paediatric oncology procedures.

11.1.2. Neonatology

Summary of committee discussion:

Procedural topics were discussed and an update provided on the ongoing public consultation of the concept paper with respect to the need of revision of the neonatal guideline which is open until 16 December 2018.

11.1.3. Inventory

Summary of committee discussion:

The group continued discussion on the criteria to be used for the assessment of unmet needs in paediatrics

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the November 2018 meeting

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dirk Mentzer	Chair	Germany	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Koenraad Norga	Member (Vice-Chair)	Belgium	No participation in final deliberations and voting on:	Gepotidacin - EMEA-002443-PIP01-18, Gepotidacin - EMEA-002443-PIP02-18
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Suzana Mimica Matanovic	Alternate	Croatia	No interests declared	
Georgios Savva	Member	Cyprus	No interests declared	
Jaroslav Sterba	Member	Czech Republic	No interests declared	
Kirstine Moll Harboe	Member	Denmark	No interests declared	
Mona Ring Gatke	Alternate	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Ann Marie Totterman	Member	Finland	No interests declared	
Sylvie	Member	France	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Benchetrit				
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member	Germany	No interests declared	
Yuansheng Sun	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Alessandro Jenkner	Alternate	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	
Sigita Burokiene	Member	Lithuania	No interests declared	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Maaike van Dartel	Member	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	
Marek Migdal	Member	Poland	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesús Fernández Cortizo	Alternate	Spain	No interests declared	
Ninna Gullberg	Member	Sweden	No interests declared	
Eva Agurell	Alternate	Sweden	No interests declared	
Angeliki Siapkara	Member	United Kingdom	No interests declared	
Martina Riegl	Alternate	United Kingdom	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No interests declared	
Catherine Cornu	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Doina Plesca	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Günter Karl-Heinz Auerswald	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Paola Baiardi	Alternate	Patients' Organisation Representative	No restrictions applicable to this meeting	
Michal Odermarsky	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared	
Catriona Elisabeth Baker	Expert - in person*	United Kingdom	No interests declared	
Shiva Ramroop	Expert - in person*	United Kingdom	No interests declared	

* Experts were only evaluated against the agenda topics or activities they participated in

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/